CL2020001850A1 - Vectores inmunoevasivos y uso para terapia génica. - Google Patents
Vectores inmunoevasivos y uso para terapia génica.Info
- Publication number
- CL2020001850A1 CL2020001850A1 CL2020001850A CL2020001850A CL2020001850A1 CL 2020001850 A1 CL2020001850 A1 CL 2020001850A1 CL 2020001850 A CL2020001850 A CL 2020001850A CL 2020001850 A CL2020001850 A CL 2020001850A CL 2020001850 A1 CL2020001850 A1 CL 2020001850A1
- Authority
- CL
- Chile
- Prior art keywords
- immunoevasive
- vectors
- gene therapy
- envelope
- viral particle
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
- 230000003611 immunoevasive effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
- C12N2750/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616167P | 2018-01-11 | 2018-01-11 | |
| US201862768779P | 2018-11-16 | 2018-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001850A1 true CL2020001850A1 (es) | 2020-12-04 |
Family
ID=65444323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001850A CL2020001850A1 (es) | 2018-01-11 | 2020-07-10 | Vectores inmunoevasivos y uso para terapia génica. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200338216A1 (https=) |
| EP (1) | EP3737768A1 (https=) |
| JP (2) | JP7406253B2 (https=) |
| KR (1) | KR20200128519A (https=) |
| CN (1) | CN111836896A (https=) |
| AU (1) | AU2019206639A1 (https=) |
| BR (1) | BR112020014093A2 (https=) |
| CA (1) | CA3088897A1 (https=) |
| CL (1) | CL2020001850A1 (https=) |
| IL (1) | IL275951A (https=) |
| MX (1) | MX2020007390A (https=) |
| RU (1) | RU2020126574A (https=) |
| SG (1) | SG11202006298XA (https=) |
| WO (1) | WO2019140311A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4118219A4 (en) * | 2020-03-11 | 2024-04-17 | Shanghai Belief-Delivery Biomed Co., Ltd. | Novel use of aspirin compound in increasing nucleic acid expression |
| US20230355803A1 (en) * | 2020-06-24 | 2023-11-09 | Chameleon Biosciences, Inc. | Extracellular vesicles with immune modulators |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| WO2023028035A1 (en) * | 2021-08-23 | 2023-03-02 | University Of Florida Research Foundation, Incorporated | Lipid enveloped recombinant aav particles for gene therapy use |
| EP4660308A1 (en) * | 2023-01-31 | 2025-12-10 | Synplogen Co., Ltd. | Helper gene |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8672198A (en) | 1997-07-31 | 1999-02-22 | Chiron Corporation | Method enabling readministration of aav vector via immunosuppression of host |
| WO1999055893A1 (en) | 1998-04-29 | 1999-11-04 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| WO2006138670A2 (en) | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
| JP4691611B1 (ja) | 2010-01-15 | 2011-06-01 | 富士フイルム株式会社 | 有機電界発光素子 |
| WO2011106376A2 (en) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Use of microvesicles in the treatment of medical conditions |
| JP7242180B2 (ja) * | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| CN104887717B (zh) * | 2015-06-04 | 2019-05-31 | 爱康得生物医学技术（苏州）有限公司 | 一种免疫增强试剂 |
| WO2017136764A1 (en) * | 2016-02-05 | 2017-08-10 | The General Hospital Corporation | Hybrid system for efficient gene delivery to cells of the inner ear |
-
2019
- 2019-01-11 BR BR112020014093-7A patent/BR112020014093A2/pt not_active IP Right Cessation
- 2019-01-11 EP EP19705841.5A patent/EP3737768A1/en not_active Withdrawn
- 2019-01-11 AU AU2019206639A patent/AU2019206639A1/en not_active Abandoned
- 2019-01-11 CA CA3088897A patent/CA3088897A1/en active Pending
- 2019-01-11 CN CN201980018276.3A patent/CN111836896A/zh active Pending
- 2019-01-11 RU RU2020126574A patent/RU2020126574A/ru unknown
- 2019-01-11 WO PCT/US2019/013361 patent/WO2019140311A1/en not_active Ceased
- 2019-01-11 JP JP2020538958A patent/JP7406253B2/ja active Active
- 2019-01-11 KR KR1020207022774A patent/KR20200128519A/ko not_active Ceased
- 2019-01-11 SG SG11202006298XA patent/SG11202006298XA/en unknown
- 2019-01-11 US US16/961,500 patent/US20200338216A1/en not_active Abandoned
- 2019-01-11 MX MX2020007390A patent/MX2020007390A/es unknown
-
2020
- 2020-07-09 IL IL275951A patent/IL275951A/en unknown
- 2020-07-10 CL CL2020001850A patent/CL2020001850A1/es unknown
-
2023
- 2023-09-08 JP JP2023146391A patent/JP2023160938A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200128519A (ko) | 2020-11-13 |
| US20200338216A1 (en) | 2020-10-29 |
| JP2021510522A (ja) | 2021-04-30 |
| WO2019140311A1 (en) | 2019-07-18 |
| BR112020014093A2 (pt) | 2020-12-01 |
| EP3737768A1 (en) | 2020-11-18 |
| MX2020007390A (es) | 2020-10-14 |
| JP7406253B2 (ja) | 2023-12-27 |
| AU2019206639A1 (en) | 2020-08-20 |
| CA3088897A1 (en) | 2019-07-18 |
| IL275951A (en) | 2020-08-31 |
| JP2023160938A (ja) | 2023-11-02 |
| SG11202006298XA (en) | 2020-07-29 |
| RU2020126574A (ru) | 2022-02-11 |
| CN111836896A (zh) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001850A1 (es) | Vectores inmunoevasivos y uso para terapia génica. | |
| CL2017002731A1 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| CL2019000167A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado. | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| AR122050A2 (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| AR115097A1 (es) | Vectores virales adenoasociados dirigidos al hígado | |
| CL2020002809A1 (es) | Construcciones para terapia génica y métodos para su uso | |
| CO2021006301A2 (es) | Composiciones y métodos de inmunoterapia | |
| CL2022001372A1 (es) | Construcciones para terapia génica con microdistrofina y uso de las mismas. | |
| CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
| CR20200460A (es) | Suministro intracelular de biomeléculas para modificar respuestas inmunes | |
| MX2019008755A (es) | Variantes de hsd17b13 y usos de las mismas. | |
| MX2021011701A (es) | Vectores adenoasociados fabricados por ingenieria (aav) para expresion transgenica. | |
| CL2017001584A1 (es) | Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso | |
| ECSP17059343A (es) | ARNi VARIANTE | |
| PH12018500927B1 (en) | Liver-specific constructs, factor viii expression cassettes and methods of use thereof | |
| CL2021001034A1 (es) | Métodos y composiciones para terapia con células oculares | |
| MX2018007237A (es) | Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus. | |
| MX2017002900A (es) | Terapia genica de globina para el tratamiento de hemoglobinopatias. | |
| CR20190397A (es) | Método para producir anticuerpos multiespecíficos | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| AR113124A1 (es) | Sistema de expresión de paramyxoviridae | |
| CO2021007320A2 (es) | Sistemas de edición génica para editar un gen regulador de la conductancia transmembrana de la fibrosis quística (cftr) | |
| CL2021003295A1 (es) | Composiciones de virus adenoasociados para la transferencia del gen de arsa y métodos de uso de las mismas. | |
| MX2021008653A (es) | Promotores inducibles específicos del hígado y métodos para utilizar los mismos. |